August 2, 2005 Biotech set another new high today, with the Centient Biotech 200 rising 17 points to just under 3800, a climb of .45%. The index now can boast a rise of over 6% so far in 2005. Repligen added to its gains since reporting an unexpected profit last week, United Therapeutics released sharply higher numbers, Myogen said it will announce top-line results for its hypertensive drug before the end of the month, Xenoport said its restless leg syndrome drug looked good in a Phase II trial, Lilly reported Arxxant passed a diabetic retinopathy test but flunked a diabetic peripheral neuropathy trial, and Perrigo will recall $2 million worth of liquid pain and cold medications. More details...
